Protein Purification and Isolation Market By Technology (Ultrafiltration, Precipitation, Preparative Chromatography Techniques, Electrophoresis, and Western Blotting), By Application (Drug Screening, Protein-Protein Interaction Studies, Biomarker Discovery, Target Identification, Protein Therapeutics, and Disease Diagnostics and Monitoring), By Product (Instruments, Consumables, and Others), By End User (Academic Medical Institutes, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, and CROs) and By Region - Trends, Analysis and Forecast Till 2034

Report Code: PMI390620 | Publish Date: April 2024 | No. of Pages: 180

Global Protein Purification And Market Companies

Recent News:

Navigo and Mannin sign a contract in September 2022 to develop a novel affinity ligand against a novel drug for treating Covid-19. Mannin Research Inc., a division of Mannin GmbH, was contracted to create a Precision X affinity ligand against an angiopoietin-fusion protein and complement four binding proteins for use in GMP production. Navigo Proteins is a protein engineering company that develops affinity ligands for custom chromatography solutions.
Novel glucagon-like peptide-1 drugs were developed in September 2022 to treat type 2 diabetes. These drugs have the potential to stimulate pancreatic beta cell synthesis, suppress insulin secretion, and release glucagon, all of which can effectively treat type 2 diabetes. Nevertheless, dipeptidyl peptidase-4 readily breaks down natural glucagon-like peptide-1 in the human body, restricting its therapeutic impact on diabetes mellitus type 2.